Martha Clokie’s Post

I am happy that we've reached this significant milestone at Epistudia: obtaining Full Online Accreditation from the European Agency for Higher Education and Accreditation (EAHEA). #systematicreview #metaanalysis #learningexperience #lifelonglearning #healthsciences #epidemiology #medicalresearch #evidence #evidencebased #science #physicians #clinicians #publichealth #healthcare #policymaking

The final manuscript is up in JDSC. Interesting to think that anti-inflammatory management around calving may positively affect immune system functions. Much more research is needed, let's get down to work 💪 ! https://lnkd.in/eNUWr2Rq

Really excited to share this preprint, the first of my PhD! Interesting insights into the genome-wide effects of fluoroquinolone-induced stress on the pneumococus. Check it out here: https://lnkd.in/dMTjN5nu

There is significant progress on the journey to #endTB and can be hopeful as we build our capacity to prevent it by scaling up TB Preventive Therapy, High quality screening by leveraging the Digital X-Ray Technology, early TB detection by onboarding alternative sample types and newer cost effective technologies, shorter yet effective TB treatment for both Susceptible and Resistant TB strains, Health education among others. We appreciate all the stakeholders, especially the valuable advocates, scientists, researchers, funding agencies, governments and the implementing mechanisms. FIND The Global Fund USAID Centers for Disease Control and Prevention Cepheid

Five ways science is tackling the #AntibioticResistance crisis “Humans are locked in an arms race with microbes, but scientists are pursuing diverse approaches to keep one step ahead or slow down the competition. Researchers are optimistic that a multipronged approach can help to turn the tide (see ‘Innovation gap’). Here, Nature profiles five of the strategies that scientists are pursuing.” https://lnkd.in/gS9q3Jvv

🧐 What do we know about phages & neutrophils? Do they help each other? Do they get in each other's way? Who can keep track? 🔎This week in C&T we take a look at 3 recent phage-neutrophil papers and what they found. https://t.co/vpnLm5q2vs

Glad to share our work on diagnostic target product profiles (TPPs) for leprosy at the Leprosy Research Initiative Spring Meeting. TPPs are an important advancement of leprosy diagnostics, as they play a critical role in guiding the innovation and optimization of new tools. By establishing clear, evidence-based criteria, TPPs provide a roadmap for researchers and developers, ensuring that new diagnostics meet the specific needs of leprosy diagnosis and management. Learn more about these TPPs in our paper, recently published in the #WHO Bulletin Journal. Coauthors include ALM's Dr. Sundeep Chaitanya Vedithi and Dr. Sunil Anand: https://lnkd.in/epFEq49P #leprosy #skinNTDs #WHO #diagnostics #research #researchanddevelopment

I’m exited too, Ebba Rosendal that the relationship between changes in hyaluronic acid and SARS-CoV-2 infection is explored. Hopefully this will give more clues Re: the connection between viral infections and connective tissue disease in general 🙏🏼🤞🏽✨ ”SARS-CoV-2 infection causes a dysregulated HA metabolism, leading to increased HA production. Our findings provide valuable insights into the pathogenesis of SARS-CoV-2 and suggest that targeting HA metabolism could offer new therapeutic avenues for managing COVID-19.” ”Corticosteroids are known to be effective in reducing HA levels in other inflammatory syndromes, thus, clearance of HA may be an important consequence of corticosteroid treatment in the resolution of COVID-19.” ”A sex comparison of HA plasma concentrations in the acute phase showed a similar increase in HA in severe COVID-19 in women and men. However, the HA levels remained higher among women compared to men in the convalescent phase of mild COVID-19.” ”We showed that despite an overall reduction in systemic HA concentrations during the convalescent phase (≥12 weeks), the plasma levels did not normalize in either mild or severe COVID-19 patients and remained significantly higher compared to the control group. Prior studies have demonstrated an elevation of HA concentration associated with disease severity in the acute phase of COVID-19 (11–14), but the long-term consequences of COVID-19 on HA levels have not previously been thoroughly investigated. The tissue half-life of HA ranges from half a day to 2–3 days, and the half-time in blood is even shorter (28). The sustained elevation of plasma HA concentrations demonstrated here, therefore, suggests an imbalance in the production and degradation of HA that remains for at least 12 weeks after disease onset, even after mild disease. ” ”The molecular mechanisms behind the observed increase in HA synthesis upon SARS-CoV-2 infection remain to be clarified. Based on the results of this study, we here propose a model in which SARS-CoV-2 infection causes transcriptional changes of genes involved in HA metabolism, which are partially counteracted by corticosteroid treatment. In our human in vitro 3D-lung model, SARS-CoV-2 infection caused an upregulation of the transcription factors EGR1 and EGR2, and we hypothesize that this in turn may activate the expression of HA synthases HAS2 and HAS3. At the same time, SARS-CoV-2 infection decreased the degrading hyaluronidases.”

My article title: Respiratory Syncytial Virus (SRV) Mechanism of Infection, Symptoms, Diagnostics and Prevention” That was published in the Journal. EC Pulmonology and Respiratory Medicine 12 (8)1-9 (2023) reached 20 reads: Abstract: Respiratory Syncytial Virus (RSV) is belonged to the family paramyxoviridae. This family are enveloped viruses with a single-stranded, negative-sense RNA genome (-RNA) directed by RNA polymerase. RSV is a common infection that spread by air droplets,and close contact. Mainly, infects nose, throat, lungs, and breathing passages causing mild cold-like symptoms, with short breath that are clinically indistinguishable from other viral respiratory infections. The virus infects infants, young children, immuno-compromise patients and old people (over 60 years and older). Most patients recover in a week or two, but sometimes it can be serious with severe infections such as bronchiolitis and pneumonia that might cause morbidity and mortality. RSV is epidemic infection occurred in winter and early spring. RSV infection can be detected by culture methods of fluid sample (respiratory specimen), and can be detected in blood sample after the infection by measuring the level of antibodies (immunoglobulins), this is in addition to rapid detection methods. Over-the-counter fever reducers and pain relievers, such as acetaminophen or ibuprofen are commonly used for managing the fever and pain. This is plus drinking enough fluids to prevent dehydration. Some medications to ease breathing such as bronchodilators are commonly used to treat long term RSV infection where the patient airways (bronchi) become narrow and inflamed. These bronchodilators medicines are muscle relaxation that widen the lung airway. Food and Drug Administration (FDA)approved antiviral medication Ribavirin for pediatric patients with severe lower respiratory infections. This is in addition to the early approved antiviral medication Palivizumab. Recently FDA approved RSV vaccines ABRYSVO and AREXVY for 60 years and older for the prevention of lower respiratory tract disease (LRTD) caused by this RSV infection. Citation: Osama O Ibrahim. “Respiratory Syncytial Virus (SRV) Mechanism of Infection, Symptoms, Diagnostics and Prevention”. EC Pulmonology and Respiratory Medicine 12.8 (2023): 01-09. (2) (PDF) Respiratory Syncytial Virus (SRV) Mechanism of Infection, Symptoms, Diagnostics and Prevention. Available from: https://lnkd.in/gnaUV7GD... [accessed Mar 16 2024].

Who will be at the BSAC SPRING CONFERENCE & AGM  EFFECTIVE ANTIMICROBIAL MANAGEMENT: THE WHAT, WHY & HOW? Come visit our stand to learn about Lodestar - UTI POC testing in 35 minutes! #AMResistance #PublicHealthW #MicrobioSoc #AntibioticResis #BSACandJAC #UTI #microbiology #AntimicrobialResistance